PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES

The influenza virus is highly contagious diseases of people, birds and mammals. Approximately 250 000– 500 000 deaths are caused by influenza epidemics worldwide yearly, and the death number may be up to millions in a possible influenza pandemic. Vaccination is the most cost-effective way to reduce...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. V. Dukhovlinov, O. A. Dobrovolskaia, A. I. Orlov
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2017
Materias:	influenza virus universal vaccine recombinant proteins hemagglutinin immunogenicity chromatography Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/b3304f55215c4adcbcb17b39d52147b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3304f55215c4adcbcb17b39d52147b3
record_format	dspace
spelling	oai:doaj.org-article:b3304f55215c4adcbcb17b39d52147b32021-11-22T07:09:48ZPRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES2220-76192313-739810.15789/2220-7619-2017-2-117-122https://doaj.org/article/b3304f55215c4adcbcb17b39d52147b32017-06-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/511https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398The influenza virus is highly contagious diseases of people, birds and mammals. Approximately 250 000– 500 000 deaths are caused by influenza epidemics worldwide yearly, and the death number may be up to millions in a possible influenza pandemic. Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the development and production of pandemic influenza vaccines are response time and production capacity as well as vaccine efficacy and safety. Reverse genetics techniques can speed up the generation of seed viruses and new mathematical modelling methods improve vaccine strain selection. Using vaccines based on recombinant proteins, we avoid the risks associated with the introduction of the virus into the body, even inactivated. In this paper, we have got a highly purified recombinant fusion protein composed of fragments of the hemagglutinin of influenza viruses A and B. As adjuvant we used components of flagellin. We used the most immunogenic and conserved areas of hemagglutinin H1, H3, H5 and B, which cause the formation of specific antibodies which can cross-react with homologous epitopes among the various strains of influenza A and B. Vaccine efficacy is increased by using multiple epitopes of various proteins. The aim of this study was to clone and express the hybrid recombinant protein Flu-Chim, containing immunogenic epitopes of influenza A/H1N1, A/H3N2, A/H5N1 and B fused with fragments of flagellin in Escherichia coli expression system and its subsequent purification. During the study was created high-yield E. coli strain, which produces the recombinant protein Flu-Chim, selected the optimal protocol of induction of the gene encoding the protein. The protein was purified using metal affinity chromatography. The purity of the final preparation reached 98%. In the future, we are going to study the immunogenic properties of the protein and use it as a component of the candidate vaccine against influenza.I. V. DukhovlinovO. A. DobrovolskaiaA. I. OrlovSankt-Peterburg : NIIÈM imeni Pasteraarticleinfluenza virusuniversal vaccinerecombinant proteinshemagglutininimmunogenicitychromatographyInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 7, Iss 2, Pp 117-122 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	influenza virus universal vaccine recombinant proteins hemagglutinin immunogenicity chromatography Infectious and parasitic diseases RC109-216
spellingShingle	influenza virus universal vaccine recombinant proteins hemagglutinin immunogenicity chromatography Infectious and parasitic diseases RC109-216 I. V. Dukhovlinov O. A. Dobrovolskaia A. I. Orlov PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
description	The influenza virus is highly contagious diseases of people, birds and mammals. Approximately 250 000– 500 000 deaths are caused by influenza epidemics worldwide yearly, and the death number may be up to millions in a possible influenza pandemic. Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the development and production of pandemic influenza vaccines are response time and production capacity as well as vaccine efficacy and safety. Reverse genetics techniques can speed up the generation of seed viruses and new mathematical modelling methods improve vaccine strain selection. Using vaccines based on recombinant proteins, we avoid the risks associated with the introduction of the virus into the body, even inactivated. In this paper, we have got a highly purified recombinant fusion protein composed of fragments of the hemagglutinin of influenza viruses A and B. As adjuvant we used components of flagellin. We used the most immunogenic and conserved areas of hemagglutinin H1, H3, H5 and B, which cause the formation of specific antibodies which can cross-react with homologous epitopes among the various strains of influenza A and B. Vaccine efficacy is increased by using multiple epitopes of various proteins. The aim of this study was to clone and express the hybrid recombinant protein Flu-Chim, containing immunogenic epitopes of influenza A/H1N1, A/H3N2, A/H5N1 and B fused with fragments of flagellin in Escherichia coli expression system and its subsequent purification. During the study was created high-yield E. coli strain, which produces the recombinant protein Flu-Chim, selected the optimal protocol of induction of the gene encoding the protein. The protein was purified using metal affinity chromatography. The purity of the final preparation reached 98%. In the future, we are going to study the immunogenic properties of the protein and use it as a component of the candidate vaccine against influenza.
format	article
author	I. V. Dukhovlinov O. A. Dobrovolskaia A. I. Orlov
author_facet	I. V. Dukhovlinov O. A. Dobrovolskaia A. I. Orlov
author_sort	I. V. Dukhovlinov
title	PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
title_short	PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
title_full	PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
title_fullStr	PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
title_full_unstemmed	PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES
title_sort	production of hybrid recombinant protein flu-chim, containing influenza viruses a and b major epitopes
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2017
url	https://doaj.org/article/b3304f55215c4adcbcb17b39d52147b3
work_keys_str_mv	AT ivdukhovlinov productionofhybridrecombinantproteinfluchimcontaininginfluenzavirusesaandbmajorepitopes AT oadobrovolskaia productionofhybridrecombinantproteinfluchimcontaininginfluenzavirusesaandbmajorepitopes AT aiorlov productionofhybridrecombinantproteinfluchimcontaininginfluenzavirusesaandbmajorepitopes
_version_	1718417998090338304

PRODUCTION OF HYBRID RECOMBINANT PROTEIN Flu-Chim, CONTAINING INFLUENZA VIRUSES A AND B MAJOR EPITOPES

Ejemplares similares